Chemistry:Azelnidipine
From HandWiki
Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)[1] In 2020.
Unlike nicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate.
Azelnidipine inhibits CYP2J2.[2]
References
- ↑ "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. September 1989. doi:10.1254/jjp.51.57. PMID 2810942. https://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/51.57?from=PubMed.Scholar search
- ↑ Marco Sisignano, Dieter Steinhilber, Michael J Parnham, Gerd Geisslinger (September 2020). "Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications". Drug Discovery Today 25 (9): 1744-1753. doi:10.1016/j.drudis.2020.07.002. PMID 32652311.
 |  |
